

REMARKS

The claims are 31-37 and 40-43, with claims 31 and 32 being independent. Claims 33 and 34 have been amended to incorporate the subject matter of claims 38 and 39. Claims 40 and 41 have been amended to recite treatment of Alzheimers disease.

Applicants acknowledge that the Examiner has indicated that claims 31-32, 35-37, and 42-43 are allowed.

Claims 38-41 were rejected under 35 U.S.C. 112, first and second paragraphs and claims 33-34 were rejected under 35 U.S.C. 112, first paragraph. Applicants respectfully submit that cancellation of claims 38 and 39 and amendment of claims 33, 34, 40 and 41 overcomes each of these rejections.

In each of the last two office actions, the Examiner has questioned the use of 5-HT₆ antagonists for the treatment of Alzheimers disease and other cognitive memory disorders. Support for the treatment of Alzheimers disease and cognitive memory disorders using 5-HT₆ receptor antagonists may be found in the documents listed in the IDS submitted herewith. As indicated in the Interview Summary, Applicants discussed the submission of these references and the amendment of the claims to recite these uses of such 5-HT₆ antagonists with the Examiner on February 12, 2008. Included in these documents is an abstract reporting pre-clinical data for a 5-HT₆ receptor antagonist compound, two citations from ClinicalTrials.org describing clinical studies using a 5-HT₆ receptor antagonist compound in Alzheimers disease and a December 2007 LSE announcement that includes a discussion of the outcome of these two clinical trials.

In view of the foregoing amendments and remarks, Applicants respectfully submit that the subject application is in condition for allowance. Applicants believe that they have addressed each of the Examiner's concerns and met each of the objections.

Application No.: 10/509,078
Group Art No.: 1624

If the Examiner has any remaining objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned attorney to resolve such issues and advance the case to issue.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Kathryn L. Sieburth', written in a cursive style.

Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5042
Facsimile (610) 270-5090
N:\kls\cases\p33024\RCE Amendment.doc